While progress has been made in establishing that acetylation is likely to be an important regulator of PD-L1, it is not yet clear how therapeutic approaches, that alter global acetylation, will affect PD-L1 function in specific cancers, tumor environments or patient cohorts and warrants further investigation [7]. This evidence concerns the gene CD274 and cancer.